Filter By Category
Archives
Share on -
AVOSENTAN
Generic Name: AVOSENTAN
ABSTRACT -
Avosentan is an investigational oral small-molecule endothelin A receptor antagonist studied for diabetic nephropathy and renal/cardiovascular disease. Its molecular formula is C₂₃H₂₁N₅O₅S. The chemical representation above shows the 2D skeletal structure.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE-
- Dosage should be determined only by a qualified healthcare professional.
- No approved public dosing regimen is established for routine clinical use unless specifically authorized in a local label.
- Clinical-study dosing, when applicable, is protocol-specific and must not be copied into routine practice.
- Do not administer outside an authorized clinical trial, compassionate-use pathway, or approved product labeling.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Fluid retention, edema, weight gain, or worsening heart failure symptoms
- Headache, dizziness, flushing, nasal congestion, or hypotension
- Anemia or changes in liver and renal laboratory parameters may occur
- Nausea, dyspepsia, or fatigue
- Hypersensitivity reactions are possible
ALLERGIC REACTIONS -
Hypersensitivity to Avosentan or related compounds/products may occur. Symptoms may include:
- Immediate urticaria, itching, flushing, or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, or breathing difficulty
- Dizziness, fainting, severe hypotension, or collapse
- Anaphylaxis, although uncommon, requires emergency medical treatment
Important: Patients who develop an allergic reaction to Avosentan should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Avosentan may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- Diuretics, antihypertensives, and heart-failure medicines require careful coordination.
- Hepatotoxic medicines may increase liver-monitoring needs.
- Other endothelin receptor antagonists should not be combined without specialist direction.
- Patients should report all medicines, supplements, and herbal products.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Monitor body weight, edema, heart-failure symptoms, liver enzymes, and renal function.
- Use caution in heart failure, significant fluid overload, hepatic impairment, or anemia.
- Avoid pregnancy exposure because endothelin receptor antagonists may carry embryo-fetal risk.
- Do not use without specialist supervision.
WARNINGS –
- Investigational status: safety and effectiveness for routine use may not be established.
- Serious or unexpected adverse events must be managed under protocol and reported promptly.
- Use only by personnel trained for the relevant formulation and administration route.
- Keep out of reach of children.
Share on -
. Developed by